

## **CONTENTS**

---

|                              |       |
|------------------------------|-------|
| <i>Preface</i> .....         | (v)   |
| <i>Acknowledgement</i> ..... | (vii) |

### **CHAPTER 1**

#### **INTRODUCTION AND SYMPTOMS**

|                           |   |
|---------------------------|---|
| Diabetic Retinopathy..... | 1 |
| Epidemiology .....        | 4 |

### **CHAPTER 2**

#### **PATHOGENESIS AND INVESTIGATIONS**

|   |    |
|---|----|
| Aetiopathogenesis .....   | 6  |
| Pathogenesis of Diabetic Retinopathy and<br>Characteristic Fundus Lesions ..... | 8  |
| Causes of Diabetic Retinopathy .....  | 13 |
| Investigations .....  | 14 |

### **CHAPTER 3**

#### **VARIOUS RECEPTORS AND THEIR ACTIVITY IN DIABETIC RETINOPATHY**

|   |    |
|---|----|
| The PKC Enzyme System.....                                      | 17 |
| Various PKC Isoforms and There Location in Different Cells..... | 19 |
| Effects of PKC Activation on Various Organs .....               | 20 |
| VEGF Receptors .....  | 21 |
| VEGF and Diabetic Retinopathy .....                             | 23 |
| Intracellular Relationship between VEGF and PKC.....            | 24 |
| Angiogenesis and Retinopathy.....                               | 25 |

### **CHAPTER 4**

#### **AVAILABLE CURRENT TREATMENTS**

|  |    |
|--|----|
| Photocoagulation.....  | 31 |
| Evidence-based Options for the Medical Treatment of<br>Diabetic Retinopathy..... | 33 |

**(x) *Contents***

---

|  |    |
|--|----|
| Limitations of Ranibizumab/Bevacizumab and their<br>Intravitreal Formulation ..... | 52 |
| Herbal Products with Anti-Angiogenic Activity.....                                 | 53 |

**CHAPTER 5**

**VARIOUS OCULAR DRUG DELIVERY SYSTEMS**

|  |    |
|--|----|
| The Anatomy and Physiology of the Eye .....  | 65 |
| Conventional Ocular Drug Delivery Constraints,<br>Ocular Barriers and Pharmacokinetics in the Eye..... | 67 |
| Formulation Approaches to Improve Ocular Bioavailability.....  | 73 |

**CHAPTER 6**

**NOVEL STRATEGIES FOR THE TREATMENT OF  
DIABETIC RETINOPATHY**

|   |     |
|---|-----|
| Noval Drug Delivery Systems .....   | 83  |
| Polymers used in Nanoscale Release Systems.....                             | 116 |
| Mechanisms of Mucoadhesion<br>(The Mucoadhesive / Mucosa Interaction) ..... | 128 |
| Various Theories of Mucoadhesion .....                                      | 130 |

**CHAPTER 7**

**FUTURE PROSPECTIVE .....** **150**

**INDEX .....** **153**